SP600125
has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways
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Cell lines
NTHY-ORI 3-1 cell line was originally obtained from normal human primary thyroid follicular epithelial cells transfected with a plasmid containing an origin-defective large T antigen SV40 genome. They express thyroid epithelial specific features, such as iodide-trapping and thyroglobulin production; Although they acquired growth factor-independency they remain non-tumorigenic in nude mice [1] . NTHY-ORI 3-1 presents diploid status with additional tetraploid clones together with very low frequency of spindle abnormalities and normal centrosomes [2] . They do not present common thyroid carcinoma genetic alterations.
TPC1 cells are derived from a papillary thyroid cancer [3] . TPC1 cells presents diploid status together with an additional minor tetraploid clone with very low frequency of spindle abnormalities and normal centrosomes [2, 4] . They express the thyroid specific transcription factors PAX8, TTF1 and TTF2 [4] [5] .
They harbour the RET/PTC1 rearrangement, a complex t(1; 10; 21) translocation and a pathogenic TERT promoter point mutation as well as a silent polymorphism in H-RAS and wild-type status for PTEN, BRAF,
CTNNB1, EGFR, K-RAS, N-RAS, RAF-1, PI3K, TP53
, and TRHB [6] [7] [8] [9] . K1 cells were derived from a primary papillary thyroid carcinoma; they share the same genetic profile of the papillary thyroid cancer derived line GLAG-66 [5, [10] [11] . They retain thyroglobulin and PAX8 expression, and significant response to TSH stimulation [5, 12] ; they are tumorigenic after inoculation in nude mice [12] .
presents mainly tetraploid status with with very low frequency of spindle abnormalities and normal centrosomes [2] . HTC/C3 were derived from cancer cells disseminated in the pleural fluid of a 44-year-old woman with a PTC-derived undifferentiated thyroid carcinoma highly resistant to chemotherapy [13] . They secrete IL1α, TGFα and PTH-like substance and have lost responsiveness to TSH; they have near-triploid karyotype with 23% polyploidy [13] . HTC/C3 express high levels of EGFR, they have heterozygous BRAF
V600E
, TERT promoter pathogenic mutation, p53 p.P152L point mutation and wild type status of RET, K-RAS, N-RAS and CTNNB1 [9, [14] [15] .
SW579 are derived from a squamous cell carcinoma of thyroid origin from a 59-year old caucasian male [16] [17] . They have p53 p.I255S point mutation and wild type status of BRAF, RET, K-RAS, N-RAS and CTNNB1 [14] .
FRO are derived from a patient with a large cell undifferentiated thyroid carcinoma [18] . Although they have WT TP53 they have a markedly decreased p53 mRNA content and do not express p53 at protein level [18] [19] . They express high levels of p27 and cyclin D3, intermediate to low levels of PTEN and harbour BRAF V600E variant and CDKN2A c.238C>T nonsense mutation causing premature stop codon [15, [20] [21] [22] .
SW1736 were established from an anaplastic thyroid cancer of a female patient. They have undetectable levels of TTF1 but high expression of several stem markers, like SOX2, OCT4, NANOG, C-MYC, SSEA4, and the ABCG2 transporter [23] [24] . They harbour a heterozygous BRAF V600E variant, TERT promoter pathogenic point mutation and have wild status for RET and PI3K [7, 9, [25] [26] . Moreover they do not express p53 at protein level and express high levels of Δnp73α [20, [27] [28] .
Hth74 cells were established from an anaplastic thyroid carcinoma [29] . They express low levels of TSHR and have undetetable levels of TTF1 and PAX8 [5, [29] [30] . They harbour TERT promoter mutation, p53 K286E point mutation, and overexpress TAp63α and TA/ΔNp73α [20, [27] [28] ; in addition they express low levels of PTEN [30] [31] . Hht74 cells have silent polimorphisms in EGFR and TRHB genes and wild type status for RET CTNNB1, BRAF, H-RAS, K-RAS, N-RAS, RAF-1, PI3K [7, 9] . 
